胃癌肝转移患者治疗过程中血管内皮细胞生长因子水平的变化

目的:检测胃癌肝转移患者治疗前后的血浆可溶性血管内皮细胞生长因子(VEGF)水平,并探讨其临床意义?方法:采用定量酶联免疫吸附试验双抗体夹心法检测43例胃癌肝转移患者治疗前后和20例浅表性胃炎患者(对照组)的血浆可溶性VEGF水平?结果:胃癌肝转移患者血浆可溶性VEGF水平显著高于对照组?经治疗后病情好转的胃癌肝转移患者[疗效评价为完全缓解(CR)或部分缓解(PR)],其血浆可溶性VEGF水平较治疗前明显下降,两者之间的差异有统计学意义(P < 0.05)?治疗后病情进展的胃癌肝转移患者[疗效评价为疾病进展(PD)],其血浆可溶性VEGF水平较治疗前明显升高,两者之间的差异有统计学意义(P < 0.05)?在经治疗后病情稳定的胃癌肝转移患者[疗效评价为疾病稳定(SD)],其血浆可溶性VEGF水平与治疗前的差异无统计学意义?结论:用ELISA方法检测血浆可溶性VEGF浓度对于评价胃癌肝转移的治疗疗效有一定的参考价值?

Change of plasma VEGF level in gastric cancer patients with liver metastasis after chemotherapy

Objective: To detect plasma vascular endothelial growth factor (VEGF) in gastric carcinoma patients with liver metastasis and investigate its significance in chemotherapy. Methods: Plasma levels of VEGF in 43 gastric cancer patients and 20 superficial gastritis patients were detected by ELISA test. Results: Plasma levels of VEGF in gastric carcinoma patients were found to be higher than those in gastritis patients. The plasma levels of VEGF in complete response (CR) or partial response (PR) gastric cancer patients decreased significantly after chemotherapy(P < 0.05). However,the plasma VEGF did not differ significantly in stable disease(SD) gastric cancer patients although they were given the same treatment. In progressive disease(PD) patients,the plasma VEGF increased after the treatment. Conclusion: The plasma VEGF level determined by ELISA could be a reference for evaluating the efficacy of treatment and progression of illness for gastric cancer patients with liver metastasis.